Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06862791 · ClinicalTrials.gov registry record · Phase 2

A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs Alone

A Phase 2 study of Obesity or Overweight, sponsored by AstraZeneca.

Active
Registry status
Phase 2
Development phase
377
Enrollment target
20
Study locations

NCT06862791: Active Phase 2 study of Obesity or Overweight, sponsored by AstraZeneca.

NCT06862791 is a Phase 2 study of Obesity or Overweight that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 377 participants, below the 803-participant average among 6 other Obesity or Overweight trials with a reported enrollment target (53% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06862791, a Phase 2 study of Obesity or Overweight, is active but no longer recruiting, sponsored by AstraZeneca.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
377 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to determine whether treatment with AZD9550 when given in combination with AZD6234 as once weekly subcutaneous (SC) injections is superior to placebo or either agent administered as monotherapy for weight loss in participants living with obesity or overweight with at least one weight-related co-morbidity.

Conditions Studied

Obesity or Overweight

Interventions

  • DRUG AZD6234
  • DRUG AZD9550
  • DRUG Placebo comparator

Study Locations (20)

California

  • Research Site - Cerritos
  • Research Site - Escondido
  • Research Site - Huntington Park
  • Research Site - Lincoln
  • Research Site - Sacramento

Alabama

  • Research Site - Dothan
  • Research Site - Vestavia Hills

Georgia

  • Research Site - Decatur
  • Research Site - Stockbridge

Indiana

  • Research Site - South Bend
  • Research Site - Valparaiso

Connecticut

  • Research Site - Waterbury

Florida

  • Research Site - Palm Harbor

Illinois

  • Research Site - Champaign

Iowa

  • Research Site - Sioux City

Trial Details

FieldValue
Enrollment Target 377 participants
Start Date 2025-02-18
Est. Completion 2026-05-25
Phase Phase 2

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06862791

The ClinicalTrials.gov registry entry for NCT06862791 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 377 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 803-participant average among 6 other Obesity or Overweight trials with a reported enrollment target (53% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Obesity or Overweight appearing as the primary indexed condition, and to 3 interventions - of which AZD6234 is the first listed.

NCT06862791 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Alabama, Georgia.

Frequently Asked Questions

What is clinical trial NCT06862791 about?

NCT06862791 is a clinical study titled "A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs Alone". The purpose of this study is to determine whether treatment with AZD9550 when given in combination with AZD6234 as once weekly subcutaneous (SC) injections is superior to placebo or either agent administered as monotherapy for weight loss in participants living with obesity or overweight with at lea...

What is the current status of trial NCT06862791?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 377 participants. The study started on 2025-02-18. Estimated completion is 2026-05-25.

What conditions does trial NCT06862791 study?

This clinical trial studies the following conditions: Obesity or Overweight.

What interventions are being tested in trial NCT06862791?

The interventions under investigation include: AZD6234 (DRUG), AZD9550 (DRUG), Placebo comparator (DRUG).

Who is sponsoring clinical trial NCT06862791?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06862791 being conducted?

This trial has 20 study locations across Alabama, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Obesity or Overweight

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Obesity or Overweight

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Related

Compare this shortlist side-by-side

Read our methodology - how this data is sourced, computed, and verified.
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.